The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

Also called NCT02316821

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 216 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02316821
Other papers using this trial's data
  • Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2024-12 DOI, PubMed 39294522, PMC11543771 In the PMC Open Access subset under CC BY.
  • Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study Clinical and experimental nephrology, 2024-03 DOI, PubMed 37962746, PMC10881689 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02316821. Randomized; double masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study
Intervention (Drug)
RTA 402
Intervention (Drug)
Placebo
Lead sponsor
Kyowa Kirin Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02316821
Content hash
8f71faececb148a6f1f8c42a0515615cd3ca3abf1144b670ac0fe83c9f5dd8af